Peptide Associates Expands Innovation Portfolio with GLP-3/Triple G Injection Therapy Program
SARASOTA, Florida – May 13, 2026 – Peptide Associates today announced the continued expansion of its innovation portfolio through the launch of its GLP-3/Triple G Injection Therapy Program, designed to support individuals seeking advanced metabolic wellness solutions through a streamlined and consumer-focused approach. As interest in peptide-based wellness therapies continues to grow nationwide, Peptide Associates […] Continue Reading

